Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
biotech
boston blog main
boston top stories
clinical trials
7
×
life sciences
national blog main
national top stories
san francisco blog main
boston
cancer
cancer drugs
deals
fda
san francisco top stories
third rock ventures
blackstone group
david goldstein
depression
epilepsy
essential tremor
hepatitis b
investing
ipo
kiran reddy
major depressive disorder
new york blog main
new york top stories
perimenopausal depression
praxis precision medicines
revolution medicines
roche
san francisco
sanofi
steven petrou
the column group
venture capital
warp drive bio
abbvie
alexion pharmaceuticals
aligos therapeutics
What
medicines
7
×
research
7
×
cancer
drug
ipo
biotech
disease
drugs
gene
genetic
new
praxis
precision
proteins
revolution
stop
targets
way
abbvie
aims
alliance
backed
biotechs
black
cancer’s
caught
cause
causing
central
ceo
clinic
cns
companies
despite
diamond
dicerna
disorder
editas
editing
eluded
Language
unset
Current search:
medicines
×
photo
×
research
×
" clinical trials "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug